Boundless Bio, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Boundless Bio's 2024 10-K filing highlights the company's focus on its lead drug candidate, BBI-355, currently in a Phase 1/2 clinical trial, and its Kinesin program, while also detailing financial results and future strategies.